SIGA gets $15M Canadian defense contract for oral TPOXX, discloses CSO retirement
SIGA Technologies reported financial results for the third quarter and first nine months of 2026 on November 9, 2026, alongside operational updates on its smallpox antiviral TPOXX.
SEC filing